Phase 3 Alzheimer's disease trials recruiting now

All Alzheimer's disease trials, every phase

Other phases for Alzheimer's disease

Phase 3 Alzheimer's disease trials

• A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
  NCT07170150 · Phase: Phase 3 · Ages: 50 Years to 90 Years · Sex: All (male and female) · 150 locations
• A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's Disease
  NCT06702124 · Phase: Phase 3 · Ages: 50 Years to 85 Years · Sex: All (male and female) · 1 location
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
  NCT07011745 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · 144 locations
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
  NCT07011732 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · 159 locations
• A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
  NCT07602582 · Phase: Phase 3 · Ages: 55 Years and older · Sex: All (male and female) · 59 locations
• A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease
  NCT06996730 · Phase: Phase 2, Phase 3 · Ages: 25 Years to 65 Years · Sex: All (male and female) · 1 location
• A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
  NCT05552157 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 37 locations
• A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
  NCT07717411 · Phase: Phase 3 · Ages: 55 Years to 80 Years · Sex: All (male and female) · 7 locations
• A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
  NCT07169578 · Phase: Phase 3 · Ages: 50 Years to 90 Years · Sex: All (male and female) · 143 locations
• A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
  NCT06647498 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 37 locations
• A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
  NCT05511363 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · 129 locations
• A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
  NCT06126224 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · 154 locations
• A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
  NCT06585787 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · 293 locations
• A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
  NCT06947941 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · 44 locations
• A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
  NCT06976216 · Phase: Phase 3 · Ages: 60 Years to 85 Years · Sex: All (male and female) · 119 locations
• A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
  NCT06976203 · Phase: Phase 3 · Ages: 60 Years to 85 Years · Sex: All (male and female) · 127 locations
• A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
  NCT06937229 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · 252 locations
• ACP-204 in Adults With Alzheimer's Disease Psychosis
  NCT06159673 · Phase: Phase 2, Phase 3 · Ages: 55 Years to 95 Years · Sex: All (male and female) · 149 locations
• Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
  NCT06563895 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 104 locations
• An Evaluation of Treatments for Sustained Clinical Response (18 Months) in Symptomatic Alzheimer's Disease
  NCT07724132 · Phase: Phase 3 · Ages: 55 Years and older · Sex: All (male and female) · 2 locations
• Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and AD
  NCT07115238 · Phase: Phase 3 · Ages: 50 Years and older · Sex: All (male and female) · 1 location
• Biomarker Exploration in Aging, Cognition and Neurodegeneration
  NCT03860857 · Phase: Phase 3 · Ages: 60 Years and older · Sex: All (male and female) · 1 location
• Clinical Analgesic Management in Dementia
  NCT07323914 · Phase: Phase 3 · Ages: 50 Years to 90 Years · Sex: All (male and female) · 1 location
• Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
  NCT07066826 · Phase: Phase 2, Phase 3 · Ages: 50 Years to 85 Years · Sex: All (male and female) · 1 location
• Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease
  NCT07062198 · Phase: Phase 3 · Ages: 50 Years and older · Sex: All (male and female) · 8 locations
• Deep Cervical Lymphatlc-Venous Anastomosis Surgery for the Treatment of Alzheimer's Disease: A Pilot Study (DIVA Study)
  NCT06530732 · Phase: Phase 3 · Ages: No age limits stated · Sex: All (male and female) · 1 location
• Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease
  NCT07571161 · Phase: Phase 3 · Ages: 55 Years to 80 Years · Sex: All (male and female) · 30 locations
• Donepezil Versus Non-drug Treatment in Alzheimer's Disease.
  NCT04661280 · Phase: Phase 3 · Ages: 50 Years and older · Sex: All (male and female) · 1 location
• Effect of CAFfeine on Cognition in Alzheimer's Disease
  NCT04570085 · Phase: Phase 3 · Ages: 50 Years and older · Sex: All (male and female) · 17 locations
• Efficacy and Safety of DMB-I (INN: Latrepirdine) in Patients With Alzheimer Type Dementia
  NCT07251023 · Phase: Phase 3 · Ages: 60 Years to 90 Years · Sex: All (male and female) · 12 locations
• Epidemiology and Biomarker Study in Alzheimer's Disease
  NCT07142954 · Phase: Phase 3 · Ages: 55 Years to 75 Years · Sex: All (male and female) · 4 locations
• Evaluate the Concordance Between PET Imaging of [18F]-APN-1607 Injection and Postmortem Brain Tissue Tau Pathology in Individuals With HV and MCI or AD.
  NCT07752784 · Phase: Phase 3 · Ages: 50 Years and older · Sex: All (male and female) · 1 location
• Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function
  NCT07422857 · Phase: Phase 3 · Ages: 50 Years and older · Sex: All (male and female) · 2 locations
• GnRH Therapy on Cognition in Down Syndrome
  NCT04390646 · Phase: Phase 2, Phase 3 · Ages: 16 Years to 50 Years · Sex: All (male and female) · 1 location
• LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome
  NCT07234695 · Phase: Phase 3 · Ages: 40 Years and older · Sex: All (male and female) · 5 locations
• Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
  NCT05397639 · Phase: Phase 3 · Ages: 50 Years to 90 Years · Sex: All (male and female) · 44 locations
• Nabilone for Agitation Blinded Intervention Trial
  NCT04516057 · Phase: Phase 3 · Ages: 55 Years and older · Sex: All (male and female) · 6 locations
• Near-infrared Light Therapy Device for Mild-Moderate Alzheimer's Disease (NirsCure-03A)
  NCT07262645 · Phase: Phase 3 · Ages: 50 Years to 85 Years · Sex: All (male and female) · 23 locations
• Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
  NCT05980949 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · 429 locations
• PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620
  NCT05456503 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Phase 3 Clinical Trial of Wujia Yizhi Granules in the Treatment of Mild-to-moderate Alzheimer's Dementia (Syndrome of Deficiency of Spleen and Kidney)
  NCT06534723 · Phase: Phase 3 · Ages: 50 Years to 80 Years · Sex: All (male and female) · 1 location
• Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
  NCT07284472 · Phase: Phase 2, Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · 49 locations
• Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
  NCT07177352 · Phase: Phase 3 · Ages: 50 Years to 90 Years · Sex: All (male and female) · 212 locations
• Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease
  NCT06254469 · Phase: Phase 3 · Ages: 45 Years and older · Sex: All (male and female) · 1 location
• [18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD
  NCT06120049 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 85 Years · Sex: All (male and female) · 4 locations
• [18F]PI-2620 Phase 3 Histopathological Study
  NCT05641688 · Phase: Phase 3 · Ages: 50 Years and older · Sex: All (male and female) · 25 locations

Common questions

What does Phase 3 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.